979-32-8 Usage
Originator
Delestrogen,Squibb,US,1954
Indications
Estradiol valerate is commercially available as an intramuscular injection as the product Delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Estradiol valerate is also available in combination with Dienogest as the commercially available product Natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding.
Manufacturing Process
2.3 parts of estradiol are mixed with 12 parts of pyridine and 10 parts of nvaleric anhydride and the mixture is heated for some time at 115°C in the oil
bath. The cooled solution is mixed with 250 parts of water, whereupon an oil
separates; this is extracted with ether. The separated ethereal solution is
washed successively with N sulfuric acid, water, N sodium carbonate solution
and water and then dried. The ether is then removed and the residue purified
by distillation in a high vacuum. The estradiol di-n-valerate forms a yellowish
oil according to US Patent 2,205,627.1 part of estradiol-3,17-n-divalerianate (boiling point at 0.01 mm = 220° to
230°C bath temperature; made, e.g., by the action of n-valeric anhydride on a
solution of estradiol in pyridine) is mixed with 50 parts of a solution of 0.5%
strength of potassium carbonate in methyl alcohol of 95% strength, and the
whole is stirred for some time at 20°C. The oily n-di-valerianate passes gradually into solution. The solution is neutralized and the precipitate is
produced by the addition of about 200 parts of water. This finely crystalline
product is filtered and washed successively with water, dilute sodium
carbonate solution and again with water. It may be further purified by
crystallization from a mixture of methyl alcohol and water. The estradiol-17-
mono-n-valerianate melts at 144° to 145°C according to US Patent 2,233,025.
Side effects
As with all pharmaceutical medicines, some unwanted effects can occur from the use of estradiol valerate tablets.Always consult a physician for medical advice before use.Common side effects may include: bloating, vomiting, nausea, breast tenderness, headache, weight changes, and mood changes.More severe side effects may include mental changes, breast lumps, vaginal bleeding, liver damage, increased thirst, and sudden vision loss.
Safety Profile
Suspected carcinogen
with carcinogenic and teratogenic data.
Experimental reproductive effects. When
heated to decomposition it emits acrid
smoke and irritating fumes. See also
ESTRADIOL.
Check Digit Verification of cas no
The CAS Registry Mumber 979-32-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 9,7 and 9 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 979-32:
(5*9)+(4*7)+(3*9)+(2*3)+(1*2)=108
108 % 10 = 8
So 979-32-8 is a valid CAS Registry Number.
InChI:InChI=1/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18?,19?,20?,21-,23-/m0/s1
979-32-8Relevant articles and documents
PROCESS FOR PREPARATION OF ESTRADIOL VALERATE AND A NOVEL CRYSTALLINE FORM A OF ESTRADIOL DIVALERATE
-
Paragraph 0056-0059, (2013/09/12)
The present invention relates to the process for the preparation of estradiol valerate (I) which involves isolation of crystalline estradiol divalerate (III) by crystallization from an alcoholic solvent.
IMPROVED PROCESS FOR PREPARATION OF ESTRADIOL VALERATE AND A NOVEL CRYSTALLINE FORM A OF ESTRADIOL DIVALERATE
-
Page/Page column 10, (2012/05/20)
The present invention relates to the process for the preparation of estradiol valerate (I) which involves isolation of crystalline estradiol divalerate (III) by crystallization from an alcoholic solvent.
Pharmaceutical combined preparation, kit and method for hormonal contraception
-
, (2008/06/13)
PCT No. PCT/DE96/01192 Sec. 371 Date Jun. 3, 1998 Sec. 102(e) Date Jun. 3, 1998 PCT Filed Jun. 27, 1996 PCT Pub. No. WO97/01342 PCT Pub. Date Jan. 16, 1997The present invention describes a two-stage pharmaceutical combined preparation for hormonal contraception containing at least 30 daily unit doses, which preparation, in its first stage, comprises as hormonal active ingredient a combination of an oestrogen preparation and, in a dose that is at least sufficient to inhibit ovulation, a gestagen preparation, in single stage form and, in the second stage comprises as hormonal active ingredient an oestrogen preparation only, wherein the first stage comprises a minimum of 25 and a maximum of 77 daily discrete or continuous unit doses and the second stage comprises 5, 6 or 7 daily discrete or continuous unit doses, and wherein the total number of daily units is equal to the total number of days of the desired cycle of a minimum of 30 and a maximum of 84 days. This combined preparation, in the form of a monthly pack, which is used for female fertility control, permits as low as possible an oestrogen content in each individual unit dose and also has a low total hormone content per cycle of administration, with high contraceptive reliability, low incidence of follicle development, and satisfactory cycle control with reliable avoidance of intermediate bleeding as well as undesired side effects.
